Kronos Bio, Inc. (NASDAQ:KRON – Get Free Report) CEO Norbert W. Bischofberger acquired 1,378,901 shares of the business’s stock in a transaction that occurred on Monday, June 10th. The shares were acquired at an average cost of $0.88 per share, with a total value of $1,213,432.88. Following the transaction, the chief executive officer now directly […]
Avoro Capital Advisors LLC lifted its position in shares of Taysha Gene Therapies, Inc. (NASDAQ:TSHA – Free Report) by 11.0% during the fourth quarter, Holdings Channel reports. The firm owned 4,355,555 shares of the company’s stock after acquiring an additional 430,555 shares during the period. Avoro Capital Advisors LLC’s holdings in Taysha Gene Therapies were […]
DLD Asset Management LP acquired a new stake in Praxis Precision Medicines, Inc. (NASDAQ:PRAX – Free Report) in the 4th quarter, according to its most recent Form 13F filing with the Securities and Exchange Commission (SEC). The fund acquired 10,000 shares of the company’s stock, valued at approximately $223,000. DLD Asset Management LP owned about […]
GlycoMimetics, Inc. (NASDAQ:GLYC – Get Free Report) was the recipient of a large drop in short interest in May. As of May 15th, there was short interest totalling 2,340,000 shares, a drop of 61.6% from the April 30th total of 6,090,000 shares. Based on an average daily volume of 1,570,000 shares, the days-to-cover ratio is […]
Centessa Pharmaceuticals plc (NASDAQ:CNTA – Get Free Report) has been given a consensus rating of “Moderate Buy” by the seven research firms that are covering the stock, MarketBeat Ratings reports. Two investment analysts have rated the stock with a hold recommendation and five have issued a buy recommendation on the company. The average 12 month […]